Provided by Tiger Fintech (Singapore) Pte. Ltd.

Healthcare

10.93
+0.05000.46%
Post-market: 10.930.00000.00%16:05 EDT
Volume:326.74K
Turnover:3.56M
Market Cap:803.22M
PE:20.62
High:10.97
Open:10.90
Low:10.73
Close:10.88
Loading ...

Viemed Healthcare Faces Rising Compliance Costs After Losing Special Reporting Status

TIPRANKS
·
12 Mar

Humanwell Healthcare's Unit Gets Nod to Trial Acute Pain Drug

MT Newswires Live
·
12 Mar

Fisher & Paykel Healthcare Launches F&P Nova Nasal Mask for Obstructive Sleep Apnea in Australia, New Zealand

MT Newswires Live
·
12 Mar

‘Healthcare Is a Blockbuster Opportunity,’ Says Cowen About Nvidia Stock

TIPRANKS
·
12 Mar

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT KEYBANC CAPITAL MARKETS VIRTUAL HEALTHCARE FORUM

PR Newswire
·
12 Mar

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Business Wire
·
12 Mar

Analysts Are Bullish on Top Healthcare Stocks: Achieve Life Sciences (ACHV), Dexcom (DXCM)

TIPRANKS
·
12 Mar

Target Healthcare REIT to Announce Half-Year Results

TIPRANKS
·
12 Mar

Community Health Systems Announces Participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Business Wire
·
11 Mar

IHH Healthcare Sees Changes in Substantial Shareholding

TIPRANKS
·
11 Mar

NorthWest Healthcare price target raised to C$5.75 from C$5.50 at National Bank

TIPRANKS
·
11 Mar

Reclaim Health Integrates AI-powered Healthcare Financial Management into WEX's Benefits Administration Solution

PR Newswire
·
11 Mar

New eHealth Research Finds Americans are Unhappy with the US Healthcare System and Open to New Ideas

PR Newswire
·
11 Mar

Over 3,500 Healthcare Practices Receive Gaps-in-Care Alerts at the Point-of-Care via Veradigm Payer Insights Solution

Business Wire
·
11 Mar

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Business Wire
·
11 Mar

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

Business Wire
·
11 Mar